Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5,029 | $7,504 | $7,293 | $13,981 |
| - Cash | $1,689 | $1,852 | $2,139 | $2,944 |
| + Debt | $2,978 | $3,781 | $6,464 | $5,654 |
| Enterprise Value | $6,318 | $9,434 | $11,618 | $16,691 |
| Revenue | $5,281 | $5,446 | $7,159 | $6,365 |
| % Growth | -3% | -23.9% | 12.5% | – |
| Gross Profit | $1,756 | $945 | $2,334 | $2,033 |
| % Margin | 33.3% | 17.4% | 32.6% | 31.9% |
| EBITDA | $1,198 | -$320 | $1,383 | $731 |
| % Margin | 22.7% | -5.9% | 19.3% | 11.5% |
| Net Income | $647 | -$783 | $727 | $241 |
| % Margin | 12.2% | -14.4% | 10.2% | 3.8% |
| EPS Diluted | 0.44 | -0.53 | 0.5 | 0.16 |
| % Growth | 183% | -206% | 212.5% | – |
| Operating Cash Flow | $2,194 | $398 | -$757 | -$7 |
| Capital Expenditures | -$203 | -$445 | -$222 | -$194 |
| Free Cash Flow | $1,991 | -$47 | -$979 | -$200 |